Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Akela Pharma Inc. AKLPF

"Akela Pharma Inc is engaged in providing contract services comprised of pharmaceutical formulation research and development, pre-clinical, clinical and commercial drug manufacturing, product development and patent litigation support."

GREY:AKLPF - Post Discussion

View:
Post by modulex on Nov 30, 2012 6:32pm

NOTE

November 30, 2012

Mr. Rudy J. Emmelot
President and Chief Executive Officer
Akela Pharma Inc.

Mr. Emmelot:

While doing my year-end 2012 financial review this morning, I am noticing that the stock (AKL-Toronto) has been halted from trading as of November 23, 2012, without notice to shareholders.

The company's website WWW.AKELAPHARMA.COM does not display any business address and only refers to the following contact information:

For Formulation Development, Manufacturing & Analytical solutions:
Toll Free 866-977-7771

For General Inquiries:

Main 512-834-0449
Fax 512-339-3050

A separate verification brought me to find out that Corporate Headquarters have moved from 11501 Domain Drive, Austin, Texas - 78758, United States, Phone: 512-531-6202 - Fax: 512-339-3050 to the State of California, at no specified address.

Oct16-2012

Contract manufacturer PharmaForm, a subsidiary of Akela Pharma, has announced plans to move from Austin, TX to the San Diego, CA area. The company offers formulation and manufacturing services for numerous dosage forms, including nasal sprays and inhalation powders.

PharmaForm President and CEO Rudy J. Emmelot commented, “We are excited about our move to San Diego and becoming part of the San Diego and California pharmaceutical and biotechnology centers. The Torreyana facility allows PharmaForm to expand beyond its current expertise of formulation development and solubility solutions for the pharmaceutical and biotechnology industries.”
The company’s corporate headquarters will be located at the new site in Torrey Pines, along with R&D, formulation, and manufacturing units.

I am questioning WHY:

The company's stock was halted on November 23, 2012?

The company did not issued a News Release about the stock halted on November 23, 2012?

The company has relocated without updating its website accordingly?

The company's telephone number indicated above (512-834-0449) refers to a telephone number in the State of Texas and the company is now in the State of California, which area code is 619?

Awaiting your reply.

Luc Proulx

LPROEXP@HOTMAIL.COM

Akela Pharma Inc. shareholder

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities